TTP399 is a potential new oral medication to lower and stabilize blood glucose in people with type 1 diabetes (T1D). If approved, TTP399 will be the first oral pill to treat T1D. In conjunction with insulin TTP399 should lower blood glucose without raising the risk of either diabetic ketoacidosis (DKA) or low blood glucose. Diabetes educator Dr. Sheri Colberg discusses the impact this new drug could have. Read more